Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Sunshine Biopharma (SBFM) EBIT Margin: 2012-2025

Historic EBIT Margin for Sunshine Biopharma (SBFM) over the last 12 years, with Sep 2025 value amounting to -11.54%.

  • Sunshine Biopharma's EBIT Margin rose 158.00% to -11.54% in Q3 2025 from the same period last year, while for Sep 2025 it was -17.35%, marking a year-over-year decrease of 244.00%. This contributed to the annual value of -16.67% for FY2024, which is 320.00% up from last year.
  • Latest data reveals that Sunshine Biopharma reported EBIT Margin of -11.54% as of Q3 2025, which was up 47.15% from -21.83% recorded in Q2 2025.
  • Over the past 5 years, Sunshine Biopharma's EBIT Margin peaked at -11.54% during Q3 2025, and registered a low of -3,184.50% during Q1 2021.
  • Moreover, its 3-year median value for EBIT Margin was -15.46% (2023), whereas its average is -18.00%.
  • In the last 5 years, Sunshine Biopharma's EBIT Margin slumped by 284,493bps in 2021 and then surged by 218,701bps in 2022.
  • Over the past 5 years, Sunshine Biopharma's EBIT Margin (Quarterly) stood at -328.52% in 2021, then crashed by 26,449bps to -593.01% in 2022, then soared by 57,755bps to -15.46% in 2023, then tumbled by 578bps to -21.24% in 2024, then skyrocketed by 158bps to -11.54% in 2025.
  • Its last three reported values are -11.54% in Q3 2025, -21.83% for Q2 2025, and -14.56% during Q1 2025.